Literature DB >> 9457828

Impact of the extent of parametrial involvement in patients with carcinoma of the uterine cervix.

H C Hsu1, S W Leung, E Y Huang, C J Wang, L M Sun, F M Fang, H C Chen.   

Abstract

PURPOSE: A scoring system is proposed to measure the extent of parametrial involvement and predict treatment outcome in patients with carcinoma of the uterine cervix. METHODS AND MATERIALS: 244 patients with FIGO Stage IIB (n = 146) or IIIB (n = 98) carcinoma of the uterine cervix were treated by radical radiotherapy from October 1987 to June 1992. Impact of the extent of parametrial involvement on outcome was studied. All patients were scored by the newly introduced scoring system described as follows: score 1, tumor extending <1/2 the distance to the pelvic side wall; score 2, tumor extending >1/2 the distance to the pelvic side wall but not to pelvic side wall; score 3, tumor extending to the pelvic side wall. The score in each patient was defined as the sum of the scores of both the left and right parametrial tumor extent.
RESULTS: There were 53, 47, 61, 34, 25, and 24 patients in score 1, 2, 3, 4, 5, and 6, respectively. All 244 patients were subdivided into three groups described as follows: score 1 and 2, group I; score 3 and 4, group II; score 5 and 6, group III. In univariate analysis, lower score groups had better overall survival rate (OS), disease-free survival rate (DFS), local control rate (LC), and distant metastasis-free rate (DMF) than higher score groups including groups I vs. II, II vs. III, or I vs. III. The differences were all statistically significant except for the difference of the DMF in group I vs. II. In multivariate analysis, score (range 1-6) was also statistically significant in OS (p < 0.0001), DFS (p = 0.0015), LC (p = 0.0032), and DMF (p = 0.0141).
CONCLUSIONS: The data suggested that the new scoring system defined by pelvic examination is a convenient, simple, and reliable method of measuring the degree of parametrial extension and predicting the outcome of patients with parametrial disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9457828     DOI: 10.1016/s0360-3016(97)00766-9

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  5 in total

1.  Tumor growth patterns on magnetic resonance imaging and treatment outcomes in patients with locally advanced cervical cancer treated with definitive radiotherapy.

Authors:  Shintaro Tsuruoka; Masaaki Kataoka; Yasushi Hamamoto; Akifumi Tokumasu; Kotaro Uwatsu; Hiromitsu Kanzaki; Noriko Takata; Hirofumi Ishikawa; Ayaka Ouchi; Teruhito Mochizuki
Journal:  Int J Clin Oncol       Date:  2019-05-11       Impact factor: 3.402

2.  Pretreatment carcinoembryonic antigen level is a risk factor for para-aortic lymph node recurrence in addition to squamous cell carcinoma antigen following definitive concurrent chemoradiotherapy for squamous cell carcinoma of the uterine cervix.

Authors:  Eng-Yen Huang; Yu-Jie Huang; Chan-Chao Chanchien; Hao Lin; Chong-Jong Wang; Li-Min Sun; Chin-Wen Tseng; Ching-Chou Tsai; Yu-Che Ou; Hung-Chun Fu; Hui-Chun Chen; Hsuan-Chih Hsu; Chang-Yu Wang
Journal:  Radiat Oncol       Date:  2012-01-30       Impact factor: 3.481

3.  Impact of treatment time-related factors on prognoses and radiation proctitis after definitive chemoradiotherapy for cervical cancer.

Authors:  Eng-Yen Huang; Hao Lin; Chong-Jong Wang; Chan-Chao Chanchien; Yu-Che Ou
Journal:  Cancer Med       Date:  2016-07-15       Impact factor: 4.452

4.  Early Clinical Outcomes, Patterns of Failure, and Acute Haematologic Toxicity of Image-Guided Volumetric Modulated Arc Therapy (IG-VMAT) in the Definitive Treatment of Locally Advanced Carcinoma Cervix.

Authors:  Irfan Ahmad; Kundan Singh Chufal; Irfan Bashir; Chandi Prasad Bhatt; Ram Bajpai; Lalit Sharma; Sandeep Rathour
Journal:  Clin Med Insights Oncol       Date:  2018-06-27

Review 5.  High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer.

Authors:  Ruifeng Liu; XiaoHu Wang; Jin Hui Tian; KeHu Yang; Jun Wang; Lei Jiang; Xiang Yong Hao
Journal:  Cochrane Database Syst Rev       Date:  2014-10-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.